Integrins regulate adhesion-dependent growth, survival and invasion of tumor cells. In particular, expression of integrin  v  3 is associated with progression of a variety of human tumors. Here we reveal a previously undescribed adhesion-independent role for integrin  v  3 in pancreatic cancer and other carcinomas. Specifically,  v  3 expressed in carcinoma cells enhanced anchorage-independent tumor growth in vitro and increased lymph node metastases in vivo. These effects required recruitment of c-Src to the  3 integrin cytoplasmic tail, leading to c-Src activation, Crk-associated substrate (CAS) phosphorylation and tumor cell survival that, unexpectedly, was independent of cell adhesion or focal adhesion kinase (FAK) activation. Pharmacological blockade of c-Src kinase activity or decreased expression of endogenous  v  3 integrin or c-Src not only inhibited anchorage-independent growth but also suppressed metastasis in vivo, yet these manipulations did not affect tumor cell migration or invasion. These data define an unexpected role for an integrin as a mediator of anchorage independence, suggesting that an  v  3 -c-Src signaling module may account for the aggressive behavior of integrin  v  3 -expressing tumors in humans.
a r t i c l e s
Although anchorage-independent growth is a hallmark of transformed cells, tumor growth and metastasis depend on tumor cell interactions with the extracellular matrix, mediated by the integrin family of adhesion receptors. Integrins promote a wide range of adhesion-dependent effects in tumor cells including proliferation, survival, migration or invasion and chemotherapeutic resistance 1 attributed to activation of FAK [2] [3] [4] [5] , which recruits other signaling molecules including c-Src 6 , a kinase whose activity is associated with enhanced malignancy 7 . After adhesion, c-Src phosphorylates CAS, a large adaptor protein implicated in cell invasion and survival [8] [9] [10] .
Integrin α v β 3 is expressed on the most aggressive tumor cells in a variety of cancers, including melanoma and carcinomas of the prostate, breast, cervix and pancreas. In melanoma, integrin α v β 3 expression initiates the transition from the benign radial growth phase to the malignant vertical growth phase 11, 12 . In both breast and prostate carcinomas, integrin α v β 3 mediates bone metastasis through enhanced tumor cell adhesion [13] [14] [15] [16] . Expression of integrin α v β 3 correlates with disease progression and shorter survival in individuals with cervical carcinoma 17 . In pancreatic ductal adenocarcinoma, integrin α v β 3 expression occurs in approximately 58% of human tumors and is associated with increased lymph node metastasis 18 .
Integrins provide context-dependent cues to both normal and transformed cells that paradoxically promote both cell survival and initiate apoptosis. Although expression of some integrins enhances malignancy, expression of others inhibits malignant progression 19, 20 . We recently demonstrated that, in some tumors, the expression of an unligated integrin induces apoptosis through recruitment and activation of caspase-8, a process termed integrin-mediated death (IMD) 21 .
Tumors lacking caspase-8 were resistant to IMD and showed increased metastatic potential 22 . Here we describe a new role for an integrin as a mediator of anchorage independence and suggest this may account for the enhanced malignancy associated with α v β 3 expression in pancreatic carcinoma and a wide array of other tumors.
RESULTS

Expression of  v  3 correlates with metastatic potential
We compared integrin α v β 3 expression in multiple matched pairs of primary tumor and lymph node metastases from individuals with pancreatic or breast cancer. In pancreatic cancer specimens, cells in the primary tumor showed heterogeneous staining for integrin α v β 3 ; however, most of the tumor cells in the lymph nodes were integrin α v β 3 positive in six of seven individuals ( Fig. 1a and Supplementary  Fig. 1a,b) . In breast cancer specimens, integrin α v β 3 was expressed in 28 of 50 primary tumors (56%); however, we observed expression of this integrin in 36 of 50 matched lymph node metastases (72%) (Fig. 1b) . In several examples, integrin α v β 3 expression was enriched in the lymph node metastases relative to the primary tumor (Fig. 1b) . These data suggest that integrin α v β 3 expression may identify the more metastatic cells within these tumors.
To directly address the role of integrin α v β 3 in tumor malignancy, we injected integrin α v β 3 -positive or integrin α v β 3 -negative GFP-labeled human pancreatic carcinoma cells into the pancreas of nude mice and evaluated primary tumor growth and spontaneous metastasis. Compared to FG (fast-growing) human pancreatic tumor cells, which lack α v β 3 , FG-β 3 cells ectopically expressing integrin α v β 3 ( Supplementary Fig. 2 ) showed higher primary tumor An integrin α v β 3 -c-Src oncogenic unit promotes anchorage-independence and tumor progression 1 1 6 4 volume 15 | number 10 | october 2009 nature medicine a r t i c l e s mass at both 6 and 8 weeks after injection (Fig. 2a) and significantly enhanced spontaneous metastasis to the hepatic hilar and mesenteric lymph nodes (Fig. 2b) . We confirmed lymph node metastases by anatomical location (Fig. 2c,d ), GFP fluorescence ( Supplementary  Fig. 3a ) and histological evaluation (Supplementary Fig. 3b ). Of note, 25% of the mice with FG-β 3 tumors developed severe ascites and wasting, emulating the morbidity associated with late stage human pancreatic carcinoma, which we did not observe in mice with FG tumors lacking α v β 3 integrin (data not shown). In support of these findings, knockdown of endogenous β 3 in Panc-1 pancreatic cancer cells (Supplementary Fig. 4a ) significantly inhibited metastasis to the liver hilar lymph nodes (Fig. 2e) and caused a modest decrease in primary tumor mass (Supplementary Fig. 4b ). In summary, these results indicate that integrin α v β 3 expression enhances the primary tumor growth and metastasis of these carcinoma cell lines.
To discern a potential mechanism to account for these findings, we analyzed the relative level of cell proliferation, apoptosis and vascular density in FG versus FG-β 3 primary tumors. In FG-β 3 tumors, the number of apoptotic cells was reduced by 62% compared to control FG tumors lacking integrin α v β 3 (Fig. 2f,g ), yet we could not detect any difference in proliferation (Fig. 2h) or vascular density ( Supplementary Fig. 5a-c) . These data indicate that α v β 3 expression is associated with increased tumor cell survival.
 v  3 enhances adhesion-independent activation of c-Src Typically, integrins initiate signaling via cell adhesion to the extracellular matrix, where they interact with immobilized matrix proteins and cluster in the plane of the membrane. This facilitates the assembly of a focal contact containing the integrin together with tyrosine kinases such as FAK or c-Src and adaptor proteins such as CAS 23 that mediate downstream signaling, leading to a wide array of cellular activities. FG cell adhesion to fibronectin depended entirely on integrin α 5 β 1 , whereas FG-β 3 cell adhesion was mediated by either integrin α 5 β 1 or integrin α v β 3 ( Supplementary Fig. 6a ). After adhesion to fibronectin, we identified two prominent phosphoproteins of approximately 60 and 130 kDa in the FG-β 3 Triton-insoluble lysate relative to the FG control (Fig. 3a) . We analyzed the 60-kDa phosphoprotein by immunoblotting with an antibody directed against activated Src family kinases (SFK) (pTyr416). We detected a considerable increase in SFK pTyr416 immunoreactivity in FG-β 3 lysates (Fig. 3b) that we verified in focal contacts by immunostaining of adherent, permeabilized cells ( Supplementary  Fig. 6b ). The 130-kDa phosphoprotein most probably represents the SFK substrates FAK (125 kDa) and CAS (130 kDa), as both showed enhanced phosphorylation in adherent FG-β 3 cells ( Supplementary  Fig. 7a,b) . Thus, whereas both α 5 β 1 and α v β 3 integrins mediate fibronectin adhesion of FG-β 3 cells, only α v β 3 colocalizes with an activated SFK in these cells.
To determine which SFK was associated with integrin α v β 3 , we examined Triton-insoluble lysates for the SFK isoforms c-Src, Yes and Fyn. This analysis identified c-Src as the only isoform associated with integrin α v β 3 ( Fig. 3b) , suggesting that integrin α v β 3 specifically recruits and a r t i c l e s activates c-Src. To evaluate this further, we immunoprecipitated integrin α v β 3 from FG-β 3 cells, followed by immunoblotting for c-Src. Integrin α v β 3 and c-Src formed a complex ( Fig. 3c ) that was abolished when we deleted the C-terminal four amino acids from the β 3 cytoplasmic tail (759x) (Supplementary Fig. 8a ), as previously reported for the platelet integrin α IIb β 3 (ref. 24) . These results suggest that integrin α v β 3 recruits c-Src in a manner that depends on the terminal four amino acids of the β 3 subunit. We further investigated the integrin α v β 3 -mediated activation of c-Src by analyzing the kinetics of SFK activation in response to cell adhesion. Consistent with our previous findings ( Fig. 3b) , expression of integrin α v β 3 in either FG or Panc-1 cells increased SFK activity after adhesion (Fig. 3d) . However, to our surprise, integrin α v β 3 also increased SFK activation in cells maintained in suspension ( Fig. 3d and Supplementary Fig. 8b ). Unlike in adherent cells, SFK activation in cells maintained in suspension occurred independently of FAK activity ( Supplementary Fig. 8c ). These findings indicate that integrin α v β 3 recruitment of c-Src may promote anchorage-independent signaling distinct from the response induced by this integrin in adherent cells, as measured by FAK activation.
 v  3 promotes anchorage independence through c-Src
Growth in anchorage-independent conditions is a hallmark of tumor cell transformation and is suggested to have a role in metastasis 25, 26 . Given our findings that α v β 3 activates c-Src in nonadherent FG-β 3 cells, we considered whether this might provide an anchorageindependent growth advantage in soft agar. Notably, we found that FG-β 3 cells formed approximately twice as many colonies as FG cells (Fig. 4a,b ), yet these cells showed no change in their growth rate when maintained in adherent culture conditions (Supplementary Fig. 9a ). In fact, ligation of integrin α v β 3 did not contribute to the anchorage-independent growth advantage of FG-β 3 cells, as neither blockade of integrin α v β 3 with the functionblocking monoclonal antibody LM609 (refs. 27,28) nor expression of a β 3 D119A mutant incapable of binding ligand 29 inhibited colony formation ( Supplementary Figs. 9b and 10a-c) . We obtained similar results after integrin α v β 3 expression in the α v β 3 -negative MiaPaca-2 human pancreatic cell line ( Supplementary Fig. 11a ), whereas knockdown of endogenous β 3 in Panc-1 cells significantly reduced their anchorage-independent growth (Fig. 4c) . These effects were also extended to tumor cells of distinct histological origin, as integrin α v β 3 expression mediated similar effects on soft agar colony formation in both breast and cervical cancer cell lines ( Supplementary  Fig. 12a-f ). Enhanced colony formation was associated with increased survival of integrin α v β 3 -expressing cells (Fig. 4d) , as observed in vivo ( Fig. 2f-h ), and not from increased proliferation ( Supplementary  Fig. 11c ). In contrast, FG and FG-β 3 cells attached to fibronectin showed identical levels of apoptosis in response to either gemcitabine (Fig. 4e) or a Fas-specific antibody (Fig. 4f) , suggesting that integrin α v β 3 provides a specific survival benefit under anchorage-independent growth conditions.
To investigate whether integrin α v β 3 -mediated, anchorageindependent survival was c-Src dependent, we placed cells in suspension culture in the presence or absence of dasatinib, a clinically approved SFK inhibitor. Treatment of FG-β 3 cells with dasatinib reduced colony formation of FG-β 3 cells to the level observed for FG cells (Fig. 5a) , suggesting that c-Src activity has a role in the α v β 3 anchorage-independent growth advantage of FG-β 3 cells. Notably, dasatinib had no effect on FG cell anchorage-independent growth, despite markedly inhibiting SFK activity in these cells ( Supplementary  Fig. 13 ). We also observed a similar result in MP-2 cells (Supplementary a r t i c l e s Fig. 14a,b) . In support of this pharmacological data, knockdown of c-Src in FG-β 3 cells (Supplementary Fig. 15 ) specifically inhibited integrin α v β 3 -mediated colony formation to the level observed in FG cells (Fig. 5b) . Next, we considered whether the c-Src-α v β 3 complex in FG-β 3 cells might have a role in integrin α v β 3 -mediated, anchorage-independent colony formation. To test this, we expressed a truncation mutant of integrin β 3 (759x) that fails to interact with c-Src 24 ( Supplementary Fig. 8a ). Cells expressing this mutant failed to enhance soft agar colony formation compared to cells expressing the wild-type receptor (Supplementary Fig. 16 ).
In adherent cells, FAK localizes to integrin focal contacts where it recruits and activates c-Src, resulting in phosphorylation of c-Src substrates, including CAS, and promotion of cell proliferation and migration 8, 9 . Although these effects occur in FG-β 3 cells attached to fibronectin (Supplementary Fig. 7a,b) or vitronectin (data not shown), FG-β 3 cells maintained in suspension show increased CAS phosphorylation (Fig. 5c) in the absence of FAK activation (Supplementary Fig. 8c ). However, CAS phosphorylation under these conditions was c-Src dependent, as it was abolished by knockdown of c-Src (Fig. 5c) . FG-β 3 cells in suspension also exhibited increased phosphorylation of Akt and ERK in a manner independent of c-Src (Fig. 5c) . These findings indicate that α v β 3 expression activates both c-Src-dependent and c-Src-independent signaling pathways, yet only the c-Src-dependent pathway leads to increased anchorageindependent growth and CAS phosphorylation.
We next considered whether CAS was required for integrin α v β 3 -mediated colony formation in soft agar. Knockdown of CAS with small interfering RNA (siRNA) oligonucleotides specifically lowered colony number in FG-β 3 cells compared to FG cells (Fig. 5d,e) . We further considered whether c-Src-dependent phosphorylation of CAS was required for integrin α v β 3 -mediated colony formation. To test this hypothesis, we expressed a dominant-negative mutant version of CAS in both FG and FG-β 3 cells in which all fifteen c-Src tyrosine phosphorylation sites within the CAS substrate domain were mutated to phenylalanines (CAS Y1-15F) 30 ( Supplementary   Fig. 17) . We embedded cells expressing this mutant in soft agar and assessed colony formation. As expected, control FG-β 3 cells showed an approximately twofold increase in colony number compared to FG cells (Fig. 5f) . FG-β 3 cells expressing the CAS Y1-15F mutant showed no such increase in colony formation (Fig. 5f) . These findings indicate that integrin α v β 3 -mediated activation of c-Src promotes increased anchorage-independent growth on the basis of its capacity to phosphorylate the CAS substrate domain.
c-Src mediates  v  3 tumor cell survival and metastasis
To determine whether integrin α v β 3 -mediated c-Src activation can lead to increased tumor malignancy, we injected FG and FG-β 3 cells expressing nonsilencing or c-Src short hairpin RNAs (shRNAs) into the pancreases of nude mice and analyzed tumor growth and metastasis after 8 weeks. Although c-Src knockdown reduced primary tumor mass in both FG and FG-β 3 cells (Fig. 6a) , it specifically blocked the metastatic advantage of the FG-β 3 cells (Fig. 6b) . Mechanistically, this seems to be due to effects on c-Src-dependent cell survival (Fig. 6c) but not proliferation (Fig. 6d) . The c-Src binding site on the β 3 tail is crucial for the in vivo effects of integrin α v β 3 expression, as FG-759x cells formed tumors that were only 3% the mass of FG-β 3 cells (Supplementary Fig. 18a,b) . These data indicate that the in vivo effects of integrin α v β 3 expression require c-Src and its interaction with the β 3 cytoplasmic tail.
To validate the therapeutic relevance of our findings, we compared the SFK and Abl inhibitor dasatinib with the Abl inhibitor imatinib for their ability to decrease tumor burden and metastasis of α v β 3 -expressing tumors. We established orthotopically injected FG-β 3 tumor cells for 2 weeks before dosing with vehicle (twice daily), 30 mg per kg body weight dasatinib (twice daily) or 50 mg per kg body weight imatinib (once a day) by oral gavage for 4 weeks. Dasatinib treatment inhibited primary tumor mass relative to the vehicle control, whereas imatinib had no effect (Fig. 6e) . Although the incidence of metastasis to the hepatic hilar lymph node was relatively unchanged (incidence of metastasis: dasatinib, 7 of 12 mice; vehicle, 9 of 12 mice; imatinib, 10 of 12 mice), the mass of the metastatic lesions was significantly reduced (Fig. 6f,g ).
Previous studies have linked integrin α v β 3 expression or c-Src activation with increased tumor cell migration and invasion 27, 31 . Although Fig. 19a,c) , integrin α v β 3 failed to potentiate invasion of FG cells into Matrigel (data not shown). Fig. 19a-c) , despite inhibiting both anchorage-independent growth and metastasis (Figs. 5b and 6b) . These findings indicate that integrin α v β 3 recruitment and activation of c-Src increases the malignant properties of pancreatic tumor cells without influencing their ability to migrate.
Knockdown or pharmacological inhibition of c-Src did not suppress the migration of either FG or FG-β 3 cells (Supplementary
DISCUSSION
Anchorage independence is a hallmark of transformed cells and is suggested to have a role in the growth of solid tumors and survival of circulating tumor cells 25, 26 . However, tumor cell adhesion and migration on extracellular matrix proteins, mediated by members of the integrin family, are linked to tumor cell growth and malignancy. Once ligated, integrins activate FAK and other downstream signaling molecules, leading to anchorage-dependent survival and proliferation 32, 33 . However, unligated integrins can negatively influence the malignant properties of tumor cells [19] [20] [21] by activation of apoptotic pathways inducing a form of death known as IMD. The tumor cells studied here have developed mechanisms to escape IMD that contribute to their metastatic behavior 22 .
Integrin α v β 3 expression is linked to metastasis in several cancers, including melanoma, as well as breast, prostate, cervical and pancreatic carcinomas [11] [12] [13] [14] [15] [16] [17] [18] , and enhances tumor cell migration, survival and increased growth factor release 27, [34] [35] [36] [37] [38] . Here we present the unexpected result that integrin α v β 3 contributes to tumor progression and metastatic potential by enhancing anchorage-independent growth. This effect requires integrin α v β 3 recruitment and activation of c-Src in a manner that is independent of tumor cell adhesion or the activation of FAK. Of note, integrin α v β 3 expression increased colony formation and cell survival in soft agar, even in the presence of a function-blocking antibody that prevents ligation to either soluble 39 or immobilized 27 ligands. In addition, expression of a mutant integrin incapable of binding ligand also showed increased anchorage independence. We observed a similar increase in cell survival in integrin α v β 3 -bearing pancreatic tumors grown in mice, suggesting that integrin α v β 3 -mediated survival contributes to both anchorage independence in vitro and tumor malignancy in vivo. Accordingly, knockdown of endogenous integrin β 3 decreased the anchorage independence and metastasis of pancreatic cancer cells.
To our surprise, we found that integrin α v β 3 promotes c-Srcdependent, but FAK-independent, phosphorylation of the CAS substrate domain in nonadherent cells. CAS phosphorylation promotes adhesion-mediated cell survival 10,40 through FAK and c-Src recruitment to integrin containing focal contacts 41 . In fibroblasts transformed with the v-Src or v-Crk oncogenes, CAS forms complexes with these molecules in a phosphorylation-dependent manner 42 , and deletion of CAS prevents v-Src-mediated transformation 43 , implicating CAS in oncogenesis. We show that knockdown of CAS or expression of a nonphosphorylated form of CAS abolished the α v β 3 -c-Src-mediated colony formation in soft agar.
Anchorage independence and tumor progression commonly result from oncogene expression. For example, the v-Src oncoprotein potently stimulates anchorage-independent growth in fibroblasts 44 , and v-Src is associated with enhanced cell invasion 8 . Expression of an activated mutant of c-Src together with integrin α v β 3 promotes the transformation of a mouse pseudoepithelial cell line, suggesting cooperativity between mutationally activated Src and α v β 3 integrin 45, 46 . However, in some circumstances, normal cellular derivatives of oncogenes, such as c-Src, also contribute to tumor progression 31 by stimulating cell migration and invasion. Here we define a previously undescribed integrin-mediated pathway leading to activation of c-Src, promoting increased anchorage independence and tumor cell malignancy that does not affect cell migration.
Previous studies have shown that the platelet integrin α IIb β 3 can recruit and activate c-Src in a manner that depends on the C-terminal portion of β 3 cytoplasmic tail 24 . We show that α v β 3 -expressing tumor cells also recruit and activate c-Src, and, similar to the platelet studies, a r t i c l e s a β 3 truncation mutant (759x) prevented c-Src recruitment to the integrin. Cells expressing this truncation mutant failed to increase anchorage-independent growth in vitro or metastasis in vivo. Although c-Src associates with integrin α v β 3 , we could not detect c-Src recruitment to other integrins in these cells, suggesting that the β 3 integrin is unique in this regard. Thus, we conclude that unligated integrin α v β 3 and its ability to recruit c-Src contribute to the malignant properties of pancreatic cancer, suggesting that α v β 3 -c-Src can function as an oncogenic unit, thereby contributing to tumor malignancy. Expression of integrin α v β 3 is associated with the metastatic potential of several cancers 18, 47, 48 . Although antagonists of integrin α v β 3 have proven efficacious as angiogenesis inhibitors in mouse tumor models 49 and are now in phase 3 clinical trials in patients with glioblastoma, our studies suggest that direct inhibition of α v β 3 ligation on tumor cells may provide limited clinical benefit, given that integrin α v β 3 activates c-Src in a ligand-independent manner. As such, we define a previously undescribed oncogenic signaling module comprised of unligated integrin α v β 3 and c-Src that occurs in a subset of tumors resistant to IMD. Furthermore, our study shows that dasatinib, a clinically approved SFK inhibitor, or c-Src knockdown not only blocked integrin α v β 3 -mediated, anchorage-independent growth of pancreatic cancer cells in vitro but also suppressed their metastatic properties in vivo. This suggests that c-Src kinase inhibition may represent a therapeutic approach for those highly malignant tumors known to express integrin α v β 3 .
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.
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ONLINE METHODS
Immunohistochemistry. We cut 8-µm sections from formalin-fixed, paraffinembedded primary tumor specimens from 18 human subjects diagnosed with pancreatic ductal adenocarcinoma (seven with matching lymph node metastases). This study was approved by the UCSD Human Research Protections Program, and informed consent was obtained from all subjects. We also stained a breast cancer tissue microarray containing 50 matched pairs of primary tumors and lymph node metastases (BR1004; BioMax). We deparaffinized and digested the sections with proteinase K (Invitrogen) for 15 min at 25 °C. before quenching with 0.3% H 2 O 2 and 0.3% normal goat serum. After washing, we blocked the sections in normal goat serum and probed with 1-in-100-diluted primary antibody overnight at 4 °C. We then incubated the sections for 45 min with a biotinylated secondary antibody (1 in 2,000) followed by 30 min in Vectastain Elite ABC Reagent (Vector Labs). Staining was performed with diaminobenzidine substrate (Vector Labs) for 1-2 min before counterstaining with hematoxylin and mounting.
Orthotopic pancreatic tumors. We generated tumors by injection of GFPlabeled human pancreatic carcinoma cells (1 × 10 6 tumor cells in 50 µl of sterile PBS) into the tails of the pancreases of 6-to 8-week-old male nude mice (purchased from the UCSD Animal Care Program nude mouse colony). See Supplementary Methods for details regarding the generation of cell lines. After 6 or 8 weeks, we resected both the primary tumors and the hepatic hilar lymph nodes. We determined primary tumor mass by measuring the wet weight of the resected tumors. We reported metastasis as the incidence of GFP-expressing cells present in the resected lymph nodes. For the dasatinib treatment experiment, we injected 36 mice with GFP-labeled FG-β 3 cells and randomized them into three groups of twelve. We allowed tumors to establish for 2 weeks before beginning dosing. We dosed the mice by oral gavage with the citric acid vehicle (twice daily), 30 mg per kg body weight dasatinib (twice daily) (Chemietek) or 50 mg per kg body weight imatinib (once a day) (Chemietek) for 4 weeks before killing the mice and measuring the mass of the primary tumors and hepatic hilar lymph nodes. All research was conducted under protocols approved by the University of California-San Diego Animal Subjects Committee and is in accordance with the guidelines set forth in the US National Institutes of Health Guide for the Care and Use of Laboratory Animals.
In vivo apoptosis and proliferation. We analyzed both apoptosis and proliferation on optimal cutting temperature medium (Tissue Tek)-embedded frozen primary tumor sections. We assessed apoptosis in vivo by TUNEL staining with the ApopTag Red kit (Millipore). We examined proliferation by immunofluorescent staining for Ki-67 using the manufacturer's instructions (Abcam). We measured both TUNEL and Ki-67 by capturing images from four 20× fields per tumor section (one section per tumor) and quantifying the number of stained cells with MetaMorph software (Molecular Devices). We normalized all data to total cell number (by staining with TOPRO-3 nuclear dye (Invitrogen)) and expressed them as the percentage TUNEL-or Ki-67-positive cells per field.
Triton-soluble and Triton-insoluble lysates. To isolate focal adhesions, we allowed serum-starved FG and FG-β 3 cells to specifically adhere and spread for 2 h on dishes coated with 5 µg ml -1 fibronectin (Sigma). We gently washed away nonadherent cells with PBS and lysed the remaining adherent cells in Triton lysis buffer (50 mM Tris pH 7.4, 150 mM NaCl, 1% Triton X-100, 50 mM NaF, 1× protease inhibitor cocktail (Roche), 2 mM phenylmethylsulphonyl fluoride and 2 mM sodium orthovanadate) to generate the Triton-soluble lysate. We prepared the Triton-insoluble lysate by washing the lysed cells twice with ice-cold PBS before adding RIPA lysis buffer (100 mM Tris pH 7.5, 150 mM NaCl, 0.1% deoxycholate, 0.1% SDS, 50 mM NaF, 1× protease inhibitor cocktail (Roche), 2 mM phenylmethylsulphonyl fluoride and 2 mM sodium orthovanadate) and concentrating the lysate to a minimal volume.
Soft agar assays. We suspended cells in 0.3% agar diluted in complete medium (DMEM with 4.5 g l -1 glucose (Mediatech) supplemented with 2 mM L-glutamine, 1% penicillin-streptomycin-fungizone, and 10% fetal bovine serum and cultured them on a bottom layer of 1% agar in complete medium in 48-or 24-well dishes. We then added additional medium and cultured cells for 7-10 d before counting colonies consisting of at least five cells from 10× fields or whole wells. For dasatinib treatment experiments, we grew colonies in vehicle (DMSO) or 50 nM, 250 nM or 1 µM dasatinib diluted in DMSO. We replaced the medium with fresh inhibitor every other day. To knockdown CAS, we transfected 5 × 10 6 FG or FG-β 3 cells with 250 nM of control or CAS-specific siRNA oligonucleotides (Qiagen) in 100 µl of Nucleofector V (Amaxa). We embedded the transfected cells in soft agar 48 h after transfection.
Suspension viability.
To directly assay for anchorage-independent survival and proliferation, we cultured 1 × 10 6 FG or FG-β 3 cells in suspension on 1% agar-coated wells in DMEM and 10% FBS for 24 and 48 h before trypsinizing, staining with trypan blue and counting viable and nonviable cells on a hemocytometer.
Statistical analyses. All data, except the metastasis experiments, are presented as the means ± s.e.m., and we evaluated statistical differences by Student's t test. For metastasis, bars represent the incidence as a percentage of total mice, and we evaluated statistics by Chi-square analysis. We evaluated colony formation in the presence of dasatinib by two-way repeated measure analysis of variance. to identify a positive interaction between the drug and the cell line. For all analyses, we considered P < 0.05 to be statistically significant. 
